Please assess the completion status of the following clinical trial:

Trial Title: Anti-CD3 x Anti-Erbitux® Armed Activated T Cells (Phase Ib) for Gastrointestinal (GI Cancer)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histological or cytological proof of colorectal or pancreatic adenocarcinoma~* Must have metastatic colorectal cancer or pancreatic cancer with stable disease after first line chemotherapy or patients with colorectal or pancreatic cancer who have progressed with standard chemotherapy options\*~* Standard chemotherapy for metastatic colorectal cancer include 5-FU/capecitabine with either oxaliplatin or irinotecan based regimen with or without bevacizumab or cetuximab.~* Standard chemotherapy for metastatic pancreatic cancer include gemzar based regimen or FOLFIRINOX (5-FU, oxaliplatin, and irinotecan)~* Prior cetuximab, panitumumab, or other monoclonal antibody therapy allowed if given 28 days prior to the 1st infusion of armed T cells~* Absolute Neutrophil Count (ANC) ≥ 1,000/mm3~* Lymphocyte count ≥ 400/mm3~* Platelet Count ≥ 50,000/mm3~* Hemoglobin ≥ 8 g/dL~* Serum Creatinine \< 2.0 mg/dl, Creatinine Clearance ≥50 ml/mm (can be calculated)~* Total Bilirubin ≤ 2 mg/dl (biliary stent is allowed)~* SGPT and SGOT \< 5.0 times normal~* LVEF ≥ 45% at rest (MUGA or Echo)~* Pulse Oximetry of \>88%~* Age ≥ 18 years at the time of consent~* Written informed consent and HIPAA authorization for release of personal health information~* Females of childbearing potential, and males, must be willing to use an effective method of contraception~* Females of childbearing potential must have a negative pregnancy test within 7 days of being registered for protocol therapy~* KPS ≥ 70% or SWOG Performance Status 0 or 1~Exclusion Criteria:~* Any chemotherapy related toxicities from prior treatment.(\> grade I per CTCAE v4.0~* Known hypersensitivity to cetuximab or other EGFR antibody~* Treatment with any investigational agent within 14 days prior to being registered for protocol therapy Protocol version: 07/13/2011 8~* Symptomatic brain metastasis~* Chronic treatment with systemic steroids or another immuno-suppressive agent~* Serious non-healing wound, ulcer, bone fracture, major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to being registered for protocol therapy~* Active liver disease such as cirrhosis, chronic active hepatitis or chronic persistent hepatitis~* HIV infection~* Positive HbsAg~* Positive Hepatitis C~* Active bleeding or a pathological condition that is associated with a high risk of bleeding~* Uncontrolled systemic disease like active infections~* Nonmalignant medical illnesses that are uncontrolled or a controlled illness that may be jeopardized by the treatment with protocol therapy~* Females must not be breastfeeding~* Patient may be excluded if, in the opinion of the PI and investigator team, the patient is not capable of being compliant~Minor changes from these guidelines will be allowed at the discretion of the attending team under special circumstances. The reasons for exceptions will be documented.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- FOLFOX6 & EGFRBi armed ATC Infusions (Type: EXPERIMENTAL): FOLFOX6: IV administration of 85 mb/m(2) oxaliplatin and 400 mg/m(2) leucovorin over 120 mins, followed by 400 mg/m(2) 5-fluorouracil (FU) bolus then 2400 mg/m(2) 5-FU as a 46 hr infusion. All patients must have central intravenous acess (e.g. mediport, PICC line) for continuous infusion of 5-FU. Adv. colorectal and pancreatic pts. w/no other standard chemo available, \& in pts who cannot receive FOLFOX chemo, immunotherapy may be given w/o antecedent chemo.~EGFRBi armed ATC Infusions: Armed ATC will be infused intravenously (IV) with the rate of infusion based on the endotoxin content of the product. All patients will be observed for at least 4 hours after an infusion. Armed ATC infusions will begin 3 weeks after chemotherapy and subsequent doses will be administered once weekly, for 3 weeks, then 12 weeks post aATC#1. Dose escalation level(per infusion): Level 0-5 billion; Level 1-10 billion; Level 2-20 billion; Level 3-40 billion

Based on this trial design, predict the completion outcome and termination type (if applicable).